Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

[1]  A. Dalgleish,et al.  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.

[2]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[3]  J. Lahuerta,et al.  Evaluation of minimal residual disease in multiple myeloma patients by fluorescent‐polymerase chain reaction: the prognostic impact of achieving molecular response , 2008, British journal of haematology.

[4]  N. Kröger,et al.  Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques , 2008, Bone Marrow Transplantation.

[5]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[6]  A. Órfão,et al.  Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation , 2008 .

[7]  N. Kröger.  Mini–Midi–Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation , 2007, Leukemia.

[8]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[9]  N. Schmitz,et al.  Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. , 2007, Haematologica.

[10]  N. Kröger,et al.  Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. , 2006, Experimental hematology.

[11]  N. Kröger,et al.  Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. , 2006, Experimental hematology.

[12]  J. Bourhis,et al.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.

[13]  H. Goldschmidt,et al.  Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. , 2006, Blood.

[14]  V. Callea,et al.  Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. , 2005, Leukemia research.

[15]  H. Goldschmidt,et al.  Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Marcos González,et al.  Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. , 2005, Haematologica.

[17]  N. Kröger,et al.  Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Blood.

[18]  M. V. van Oers,et al.  The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. , 2004, Blood.

[19]  J. Serody,et al.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Kröger,et al.  Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma , 2004, Leukemia.

[21]  U. Steidl,et al.  Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. , 2004, Haematologica.

[22]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[23]  M. Boccadoro,et al.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. , 2003, Blood.

[24]  N. Schmitz,et al.  Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM) , 2003, Bone Marrow Transplantation.

[25]  S. Mackinnon,et al.  Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  N. Kröger,et al.  Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. , 2002, Journal of hematotherapy & stem cell research.

[27]  N. Kröger,et al.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.

[28]  M. Bernard,et al.  Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. , 2002, Blood.

[29]  M. Boccadoro,et al.  Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small‐ and large‐scale Miltenyi cell sorting system , 2002, British journal of haematology.

[30]  J. Gribben,et al.  T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. , 2001, Blood.

[31]  N. Kröger,et al.  Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.

[32]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[33]  N. Kröger,et al.  Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma , 2001, British journal of haematology.

[34]  G. Martinelli,et al.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. San-Miguel,et al.  Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients , 2000, British journal of haematology.

[36]  R. Collins,et al.  Donor leukocyte infusions for multiple myeloma , 2000, Bone Marrow Transplantation.

[37]  A. Palumbo,et al.  Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Russell,et al.  Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma , 1998, Bone Marrow Transplantation.

[39]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[40]  J. Byrne,et al.  Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. , 1998, Bone marrow transplantation.

[41]  R. Storb,et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.